OA12687A - Oral pharmaceutical composition of cefpodoxime proxetil. - Google Patents

Oral pharmaceutical composition of cefpodoxime proxetil. Download PDF

Info

Publication number: OA12687A
Authority: OA; OAPI
Prior art keywords: pharmaceutical composition; composition according; agent; daim; gum
Prior art date: 2001-02-27

Application number

OA1200300220A

Other languages

English (en)

Inventor

Mukta Malhotra

Rajeev Shankar Mathur

Rajiv Malik

Original Assignee

Ranbaxy Lab Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-27

Filing date

2002-02-27

Publication date

2006-06-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11097036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12687(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-02-27 Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd

2006-06-21 Publication of OA12687A publication Critical patent/OA12687A/en

Links

LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical group N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 title abstract description 23
229960004797 cefpodoxime proxetil Drugs 0.000 title abstract description 23
239000008203 oral pharmaceutical composition Substances 0.000 title description 2
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 43
239000000203 mixture Substances 0.000 claims description 40
239000002245 particle Substances 0.000 claims description 30
239000003795 chemical substances by application Substances 0.000 claims description 16
229960005090 cefpodoxime Drugs 0.000 claims description 13
WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 claims description 13
239000003826 tablet Substances 0.000 claims description 11
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 10
239000008187 granular material Substances 0.000 claims description 10
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 10
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 10
239000001768 carboxy methyl cellulose Substances 0.000 claims description 9
229920000642 polymer Polymers 0.000 claims description 9
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
239000002775 capsule Substances 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 7
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
239000000796 flavoring agent Substances 0.000 claims description 6
235000019634 flavors Nutrition 0.000 claims description 6
-1 hydroxypropyl Chemical group 0.000 claims description 6
239000000725 suspension Substances 0.000 claims description 6
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
239000004141 Sodium laurylsulphate Substances 0.000 claims description 5
229920001525 carrageenan Polymers 0.000 claims description 5
238000009826 distribution Methods 0.000 claims description 5
239000002552 dosage form Substances 0.000 claims description 5
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 5
239000004094 surface-active agent Substances 0.000 claims description 5
229920001285 xanthan gum Polymers 0.000 claims description 5
235000010493 xanthan gum Nutrition 0.000 claims description 5
239000000230 xanthan gum Substances 0.000 claims description 5
229940082509 xanthan gum Drugs 0.000 claims description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
229920002472 Starch Polymers 0.000 claims description 4
239000011324 bead Substances 0.000 claims description 4
239000011575 calcium Substances 0.000 claims description 4
229910052791 calcium Inorganic materials 0.000 claims description 4
235000010418 carrageenan Nutrition 0.000 claims description 4
239000000679 carrageenan Substances 0.000 claims description 4
229940113118 carrageenan Drugs 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
229920000058 polyacrylate Polymers 0.000 claims description 4
230000008961 swelling Effects 0.000 claims description 4
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
108010010803 Gelatin Proteins 0.000 claims description 3
239000008273 gelatin Substances 0.000 claims description 3
229920000159 gelatin Polymers 0.000 claims description 3
235000019322 gelatine Nutrition 0.000 claims description 3
235000011852 gelatine desserts Nutrition 0.000 claims description 3
229920000591 gum Polymers 0.000 claims description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
229920000136 polysorbate Polymers 0.000 claims description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
239000007909 solid dosage form Substances 0.000 claims description 3
229940032147 starch Drugs 0.000 claims description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
244000215068 Acacia senegal Species 0.000 claims description 2
229920001817 Agar Polymers 0.000 claims description 2
241000416162 Astragalus gummifer Species 0.000 claims description 2
229920002907 Guar gum Polymers 0.000 claims description 2
229920000084 Gum arabic Polymers 0.000 claims description 2
229920000569 Gum karaya Polymers 0.000 claims description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 2
229920000161 Locust bean gum Polymers 0.000 claims description 2
241000934878 Sterculia Species 0.000 claims description 2
229920001615 Tragacanth Polymers 0.000 claims description 2
235000010489 acacia gum Nutrition 0.000 claims description 2
239000000205 acacia gum Substances 0.000 claims description 2
239000008272 agar Substances 0.000 claims description 2
229940023476 agar Drugs 0.000 claims description 2
235000010419 agar Nutrition 0.000 claims description 2
235000010443 alginic acid Nutrition 0.000 claims description 2
229920000615 alginic acid Polymers 0.000 claims description 2
239000000783 alginic acid Substances 0.000 claims description 2
229960001126 alginic acid Drugs 0.000 claims description 2
150000004781 alginic acids Chemical class 0.000 claims description 2
230000000181 anti-adherent effect Effects 0.000 claims description 2
239000003911 antiadherent Substances 0.000 claims description 2
239000002518 antifoaming agent Substances 0.000 claims description 2
239000011230 binding agent Substances 0.000 claims description 2
239000006172 buffering agent Substances 0.000 claims description 2
229920003086 cellulose ether Polymers 0.000 claims description 2
229920001577 copolymer Polymers 0.000 claims description 2
235000010417 guar gum Nutrition 0.000 claims description 2
239000000665 guar gum Substances 0.000 claims description 2
229960002154 guar gum Drugs 0.000 claims description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
235000010494 karaya gum Nutrition 0.000 claims description 2
239000000231 karaya gum Substances 0.000 claims description 2
229940039371 karaya gum Drugs 0.000 claims description 2
235000010420 locust bean gum Nutrition 0.000 claims description 2
239000000711 locust bean gum Substances 0.000 claims description 2
239000000314 lubricant Substances 0.000 claims description 2
229920000609 methyl cellulose Polymers 0.000 claims description 2
235000010981 methylcellulose Nutrition 0.000 claims description 2
239000001923 methylcellulose Substances 0.000 claims description 2
235000010987 pectin Nutrition 0.000 claims description 2
229920001277 pectin Polymers 0.000 claims description 2
239000001814 pectin Substances 0.000 claims description 2
229960000292 pectin Drugs 0.000 claims description 2
229940068965 polysorbates Drugs 0.000 claims description 2
239000003755 preservative agent Substances 0.000 claims description 2
230000002335 preservative effect Effects 0.000 claims description 2
235000010413 sodium alginate Nutrition 0.000 claims description 2
239000000661 sodium alginate Substances 0.000 claims description 2
229940005550 sodium alginate Drugs 0.000 claims description 2
235000010487 tragacanth Nutrition 0.000 claims description 2
239000000196 tragacanth Substances 0.000 claims description 2
229940116362 tragacanth Drugs 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
239000013543 active substance Substances 0.000 claims 1
239000011248 coating agent Substances 0.000 claims 1
238000000576 coating method Methods 0.000 claims 1
239000001341 hydroxy propyl starch Substances 0.000 claims 1
235000013828 hydroxypropyl starch Nutrition 0.000 claims 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
239000008109 sodium starch glycolate Substances 0.000 claims 1
229940079832 sodium starch glycolate Drugs 0.000 claims 1
229920003109 sodium starch glycolate Polymers 0.000 claims 1
239000000375 suspending agent Substances 0.000 claims 1
229940079593 drug Drugs 0.000 description 25
239000003814 drug Substances 0.000 description 25
238000004090 dissolution Methods 0.000 description 16
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
238000000034 method Methods 0.000 description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
229930006000 Sucrose Natural products 0.000 description 8
239000005720 sucrose Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000001913 cellulose Substances 0.000 description 6
239000008101 lactose Substances 0.000 description 6
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
239000002156 adsorbate Substances 0.000 description 5
235000010980 cellulose Nutrition 0.000 description 5
229920002678 cellulose Polymers 0.000 description 5
229960004106 citric acid Drugs 0.000 description 5
235000015165 citric acid Nutrition 0.000 description 5
239000012530 fluid Substances 0.000 description 5
239000000499 gel Substances 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
239000000377 silicon dioxide Substances 0.000 description 5
235000012239 silicon dioxide Nutrition 0.000 description 5
239000011734 sodium Substances 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 5
239000004299 sodium benzoate Substances 0.000 description 5
235000010234 sodium benzoate Nutrition 0.000 description 5
239000001509 sodium citrate Substances 0.000 description 5
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
239000006188 syrup Substances 0.000 description 5
235000020357 syrup Nutrition 0.000 description 5
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
239000012736 aqueous medium Substances 0.000 description 4
229940105329 carboxymethylcellulose Drugs 0.000 description 4
230000001186 cumulative effect Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
229920002785 Croscarmellose sodium Polymers 0.000 description 3
239000002253 acid Substances 0.000 description 3
238000013459 approach Methods 0.000 description 3
238000004040 coloring Methods 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
229950000033 proxetil Drugs 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
229920000858 Cyclodextrin Polymers 0.000 description 2
229920003134 Eudragit® polymer Polymers 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010053317 Hydrophobia Diseases 0.000 description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000012395 formulation development Methods 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
229920001477 hydrophilic polymer Polymers 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
239000008188 pellet Substances 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
229940083037 simethicone Drugs 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
229920003169 water-soluble polymer Polymers 0.000 description 2
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
108020004256 Beta-lactamase Proteins 0.000 description 1
KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
208000037041 Community-Acquired Infections Diseases 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
229920003157 Eudragit® RL 30 D Polymers 0.000 description 1
229920003161 Eudragit® RS 30 D Polymers 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
241000590428 Panacea Species 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
229960003022 amoxicillin Drugs 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229960000892 attapulgite Drugs 0.000 description 1
229950003588 axetil Drugs 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
239000003782 beta lactam antibiotic agent Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229940088623 biologically active substance Drugs 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001175 calcium sulphate Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
229960002620 cefuroxime axetil Drugs 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
239000004927 clay Substances 0.000 description 1
238000005056 compaction Methods 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
229940096516 dextrates Drugs 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
238000009112 empiric therapy Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000009478 high shear granulation Methods 0.000 description 1
238000005213 imbibition Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
238000011068 loading method Methods 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000003801 milling Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
229910052625 palygorskite Inorganic materials 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
235000019814 powdered cellulose Nutrition 0.000 description 1
229920003124 powdered cellulose Polymers 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
238000009877 rendering Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
238000004513 sizing Methods 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
239000007892 solid unit dosage form Substances 0.000 description 1
239000008137 solubility enhancer Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
239000001570 sorbitan monopalmitate Substances 0.000 description 1
229940031953 sorbitan monopalmitate Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000002132 β-lactam antibiotic Substances 0.000 description 1
229940124586 β-lactam antibiotics Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cephalosporin Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA1200300220A 2001-02-27 2002-02-27 Oral pharmaceutical composition of cefpodoxime proxetil. OA12687A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IN190DE2001		2001-02-27

Publications (1)

Publication Number	Publication Date
OA12687A true OA12687A (en)	2006-06-21

Family

ID=11097036

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200300220A OA12687A (en)	2001-02-27	2002-02-27	Oral pharmaceutical composition of cefpodoxime proxetil.

Country Status (14)

Country	Link
EP (1)	EP1365764B1 (de)
JP (1)	JP2004522782A (de)
KR (1)	KR20030087009A (de)
CN (1)	CN1505515A (de)
AT (1)	ATE303149T1 (de)
AU (1)	AU2002237462B2 (de)
BR (1)	BR0207640A (de)
DE (1)	DE60205870T2 (de)
EA (1)	EA006974B1 (de)
ES (1)	ES2248521T3 (de)
MX (1)	MXPA03007678A (de)
NZ (1)	NZ527867A (de)
OA (1)	OA12687A (de)
WO (1)	WO2002067943A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6766376B2 (en)	2000-09-12	2004-07-20	Sn Acquisition, L.L.C	Streaming media buffering system
ATE415150T1 (de) *	2002-08-16	2008-12-15	Orchid Chemicals & Pharm Ltd	Pharmazeutische zusammensetzung mit verzögerte freisetzung enthaltend einen cephalosporin- antibiotikum
AU2002321743A1 (en) *	2002-08-19	2004-03-03	Orchid Health Care	Sustained release pharmaceutical composition of a cephalosporin antibiotic
WO2004105728A2 (en) *	2003-05-27	2004-12-09	Ranbaxy Laboratories Limited	Solid dispersions of cefpodoxime proxetil and processes for their preparation
WO2007017895A2 (en) *	2005-05-05	2007-02-15	Lupin Limited	Stabilized oral pharmaceutical compositions of cephalosporins
MX2007014363A (es) *	2005-05-16	2009-04-15	Elan Pharma Int Ltd	Composiciones de liberacion controlada y en forma de nanoparticulas que comprenden una cefalosporina.
WO2007063552A1 (en) *	2005-12-02	2007-06-07	Lupin Limited	Stable taste masked formulations of cephalosporins
WO2008057058A1 (en) *	2006-11-10	2008-05-15	Nobel Ilac Sanayii Ve Ticaret As	Oral pharmaceutical compositions
CN101278914B (zh) *	2008-01-02	2010-06-02	海南三叶美好制药有限公司	头孢泊肟酯干混悬剂组合物及其制备方法
TR201001417A1 (tr) *	2010-02-25	2011-09-21	Sanovel İlaç San. Ve Ti̇c. A. Ş.	Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
TR201002878A2 (tr)	2010-04-13	2011-10-21	Bi̇lgi̇ç Mahmut	Sefpodoksim proksetil içeren farmasötik bileşimler.
WO2011152807A1 (en) *	2010-06-03	2011-12-08	Bilgic Mahmut	Pharmaceutical formulation comprising cefpodoxime proxetil and clavulanic acid
TR201007107A1 (tr) *	2010-08-25	2012-03-21	B�Lg�� Mahmut	Tat düzenleyici ajan içeren sefpodoksim proksetil formülasyonları.
TR201007106A1 (tr) *	2010-08-25	2012-03-21	Bi̇lgi̇ç Mahmut	Sefpodoksim proksetil formülasyonları.
TR201009168A2 (tr) *	2010-11-05	2012-05-21	Bi̇lgi̇ç Mahmut	Suda dağılan sefpodoksim proksetil formülasyonları.
HUE034511T2 (en) *	2010-12-03	2018-02-28	Nippon Soda Co	Solid dosage form with low viscosity hydroxyalkylcellulose content
JP6062422B2 (ja) *	2012-03-29	2017-01-18	杏林製薬株式会社	カプセル製剤
PT2877163T (pt)	2012-07-27	2019-05-24	Redhill Biopharma Ltd	Formulações e métodos de fabrico de formulações para utilização na evacuação colónica
CN103142506B (zh) *	2013-04-03	2015-02-25	天津医药集团津康制药有限公司	一种头孢泊肟酯颗粒剂及其制备方法
US9603804B2 (en)	2013-04-25	2017-03-28	Kyorin Pharmaceutical Co., Ltd.	Solid pharmaceutical composition
WO2014174847A1 (ja)	2013-04-25	2014-10-30	杏林製薬株式会社	固形医薬組成物
KR101509168B1 (ko) *	2013-06-10	2015-04-06	한국화학연구원	세팔로스포린 항생제의 서방형 제제 및 이를 포함하는 서방형 약제학적 조성물
CN103301075B (zh) *	2013-06-28	2015-11-18	山东罗欣药业集团股份有限公司	一种头孢克肟组合物混悬颗粒剂及其制备方法
JP6292788B2 (ja) *	2013-07-30	2018-03-14	ライオン株式会社	錠剤及び錠剤の製造方法
JP2016204260A (ja) *	2013-10-04	2016-12-08	日本曹達株式会社	錠剤の製造方法
JP6018334B2 (ja)	2014-10-23	2016-11-02	杏林製薬株式会社	固形医薬組成物
CN104771368B (zh) *	2015-04-08	2017-12-22	石家庄四药有限公司	头孢泊肟酯速释制剂及其制备方法
CN113456599A (zh) *	2020-03-30	2021-10-01	洛阳惠中兽药有限公司	一种头孢泊肟酯片的制备方法及其制备的头孢泊肟酯片
CN113952313A (zh) *	2021-08-26	2022-01-21	宁夏医科大学	一种头孢呋辛酯胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4486425A (en) *	1980-09-30	1984-12-04	Sankyo Company Limited	7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
US5929086A (en) *	1996-05-10	1999-07-27	Pharmacia & Upjohn Company	Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
AT500063A1 (de) *	1999-11-23	2005-10-15	Sandoz Ag	Beschichtete tablettenkerne
BR0112393A (pt) *	2000-06-21	2003-07-08	Internat Health Man Associates	Composições e processos para aperfeiçoamento de absorção oral de agentes antimicrobiais

2002
- 2002-02-27 BR BR0207640-3A patent/BR0207640A/pt not_active Application Discontinuation
- 2002-02-27 KR KR10-2003-7011273A patent/KR20030087009A/ko not_active Withdrawn
- 2002-02-27 OA OA1200300220A patent/OA12687A/en unknown
- 2002-02-27 AT AT02703777T patent/ATE303149T1/de not_active IP Right Cessation
- 2002-02-27 MX MXPA03007678A patent/MXPA03007678A/es unknown
- 2002-02-27 ES ES02703777T patent/ES2248521T3/es not_active Expired - Lifetime
- 2002-02-27 AU AU2002237462A patent/AU2002237462B2/en not_active Ceased
- 2002-02-27 JP JP2002567310A patent/JP2004522782A/ja active Pending
- 2002-02-27 DE DE60205870T patent/DE60205870T2/de not_active Expired - Fee Related
- 2002-02-27 CN CNA028089766A patent/CN1505515A/zh active Pending
- 2002-02-27 NZ NZ52786702A patent/NZ527867A/xx unknown
- 2002-02-27 WO PCT/IB2002/000602 patent/WO2002067943A1/en not_active Ceased
- 2002-02-27 EA EA200300937A patent/EA006974B1/ru not_active IP Right Cessation
- 2002-02-27 EP EP02703777A patent/EP1365764B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
MXPA03007678A (es)	2004-03-16
EA200300937A1 (ru)	2004-04-29
JP2004522782A (ja)	2004-07-29
EA006974B1 (ru)	2006-06-30
BR0207640A (pt)	2004-07-27
WO2002067943A1 (en)	2002-09-06
CN1505515A (zh)	2004-06-16
NZ527867A (en)	2004-12-24
ATE303149T1 (de)	2005-09-15
DE60205870T2 (de)	2006-06-29
ES2248521T3 (es)	2006-03-16
KR20030087009A (ko)	2003-11-12
EP1365764A1 (de)	2003-12-03
DE60205870D1 (de)	2005-10-06
EP1365764A4 (de)	2004-08-11
EP1365764B1 (de)	2005-08-31
AU2002237462B2 (en)	2006-05-18

Publication	Publication Date	Title
EP1365764B1 (de)	2005-08-31	Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
AU2002237462A1 (en)	2003-03-06	Oral pharmaceutical composition of cefpodoxime proxetil
JP3180350B2 (ja)	2001-06-25	β―ラクタム系抗生物質含有錠剤およびその製造法
WO2008104996A2 (en)	2008-09-04	Water dispersible pharmaceutical formulation and process for preparing the same
US6727243B1 (en)	2004-04-27	Compositions comprising cefuroxime axetil
WO2002094774A2 (en)	2002-11-28	Oxcarbazepine dosage forms
AU2004290511A1 (en)	2005-06-02	Process for preparing clopidogrel compositions
AU762840B2 (en)	2003-07-03	Pharmaceutical suspension formulation comprising amoxycillin, clavulanic acid and cellulose
CA2272402A1 (en)	1999-05-27	Granules comprising clavulanate and one or more excipients
JP2005507397A (ja)	2005-03-17	速溶性の経口製剤
JP2004315483A (ja)	2004-11-11	口腔内崩壊錠剤
KR101730865B1 (ko)	2017-04-27	레바프라잔-함유 나노입자를 포함하는 경구투여용 약학 조성물 및 그의 제조방법
EP1634586B1 (de)	2007-02-14	Schnell wasserdispergierbare und Domperidon enthaltende Tabletten
CN1295472A (zh)	2001-05-16	卡维地洛－盖仑制剂
WO2004014337A2 (en)	2004-02-19	A process for the preparation of dispersible tablet of cephalexin
AU2023378359A1 (en)	2025-03-06	An orally disintegrating tablet containing atorvastatin and process of preparing the same
KR100464210B1 (ko)	2005-01-03	세푸록심 악세틸 함유 약제학적 조성물 및 그의 제조방법
EP4316463A1 (de)	2024-02-07	Neuartige formulierung
KR20060058415A (ko)	2006-05-30	아목시실린 및 클라불란산 또는 그의 염의 혼합물 함유조성물 및 그의 제조방법
MXPA01005274A (en)	2002-03-26	Compositions comprising cefuroxime axetil